Business Wire

ABBOVE

8.9.2022 11:41:35 CEST | Business Wire | Press release

Share
WealthTech Abbove Supports Quintet Private Bank to Bring Digital Wealth Planning to Their Private Banking Clients in Belgium

The Belgian solution provider Abbove, an emerging leader in the digital transformation of the wealth management industry, announces its partnership with Quintet Group’s Belgian branch Puilaetco to provide digital wealth planning services to their private banking clients. With the opportunity of expanding services to up to six new European countries, including the Netherlands, Denmark, Germany, and the United Kingdom, this marks another step for the company in spreading its wealth planning platform, if the Belgian pilot roll-out proves successful.

Currently, over 25,000 families in Europe received access to Abbove's platform via their trusted advisor. Starting today, Puilaetco's clients, who will use the technology under the name of “Richer Life Plan”, will expand that user base. By integrating the solution into their offer, the bank's advisors can now give their clients a global overview of their family's entire assets, as well as create simulations on the evolution of their wealth and the organization of their inheritance, all of this on a digital and 24/7 accessible platform.

“Since the beginning, it has been clear that our solution and vision are fully in tune with Quintet’s ambition. At Abbove, we develop a technology that helps financial institutions throughout the entire cycle of offering holistic wealth management services: from fully understanding a client’s global situation to delivering the best solutions based on his personal needs and guaranteeing a digital and interactive client experience. Not only our solution as such, but also our ambition to make our platform available internationally found a match with Quintet who have the will to spread the solution across their network in Europe after this first deployment in Belgium”, stated Guillaume Desclée, CEO and co-founder of Abbove.

Also commenting on the new partnership is Ludivine Pilate, Country CEO of Puilaetco: "With Richer Life Plan, we are entering a new era of customized wealth advice thanks to a complete and innovative technological solution. The tool perfectly matches our desire to strengthen the relationship of trust between our clients and our bankers: they share the same level of information, an indispensable basis for our experts to offer personalized solutions in terms of wealth structuring, investment, credit, or art advice.”

After opening up to banks across Europe at the beginning of June, this is the second private banking partnership announced by Abbove in three month’s time. The wealthtech’s solution is designed to help international banking groups add a digital and global layer to their wealth services so they can improve productivity, advice quality and user experience.

_____________________

About Abbove: Abbove SA is a Belgian WealthTech that develops a collaborative wealth planning platform for financial advisors and the families they accompany. Abbove’s technology helps financial advisors to digitize their wealth management services by improving the fluidity of internal processes and the client experience of the families they serve. The platform is currently distributed by 900 advisors to over 25,000 families in Europe. Visit www.abbove.com for more information.

About Puilaetco: With nearly 200 highly qualified employees and around ten billion euros of assets under management, Puilaetco, a Quintet Private Bank (Europe) S.A. Branch is a Belgian asset manager (founded in 1868) that offers its clients a personalized approach that is both innovative and traditional. As a trusted partner, the bank has been offering efficient, personalized and responsible solutions for five generations. These services include asset management, financial and estate planning, loans and artistic asset management.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005531/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye